文献速递乳腺癌

乳房切除术后大分割放疗在乳房再造患者中的随机试验(RT CHARM)

Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).
PubMed 文献 · J Clin Oncol · 2026-10-12

针对乳房切除术后需放疗且计划乳房再造的患者,开展大分割与传统分割放疗的非劣效性随机试验,主要终点为再造并发症率。898例入组,24个月并发症率大分割组12.3% vs 传统组10.2%,差异-2.1%(95%CI -6.5~2.2),符合非劣效;36个月局部区域复发率无显著差异。

要点

  • 大分割PMRT(42.56 Gy/16次/3周)在再造患者中非劣效于传统分割(50 Gy/25次/5周)。
  • 24个月再造并发症率两组差异-2.1%(95%CI -6.5~2.2),在预设10%非劣效界值内。
  • 36个月局部区域复发率大分割1.5% vs 传统2.2%,无统计学显著差异。

核心结论

  • 16次大分割PMRT在乳房切除术后乳房再造患者中安全且非劣效于传统分割放疗。

研究设计与样本

  • 随机、非劣效性试验,纳入单侧浸润性乳腺癌计划即刻或延期再造并需PMRT的女性,1:1随机至50 Gy/25次/5周或42.56 Gy/16次/3周。
  • 2018至2021年入组898例,中位随访3.9年,825例可评估主要终点;预设非劣效界值10%,假设传统PMRT 2年再造并发症率25%。
  • 随机按即刻vs延期及自体vs仅假体再造分层。

主要发现

  • 24个月再造并发症率大分割组12.3%(52/422),传统组10.2%(41/403),估计差异-2.1%(95%CI -6.5~2.2)。
  • 无论治疗臂,仅假体再造的并发症率高于自体再造(OR=1.65)。
  • 36个月局部区域复发率大分割1.5%(95%CI 0.7~3.2),传统2.2%(95%CI 1.1~4.3),无统计学显著差异。
  • 急性和晚期毒性率无统计学差异。

临床怎么用

  • 对于计划乳房再造的乳房切除术后乳腺癌患者,可考虑使用16次大分割PMRT作为传统分割的替代方案。
  • 临床决策中需注意仅假体再造者并发症风险相对更高(OR=1.65)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with breast cancer requiring postmastectomy radiation therapy (PMRT) often desire breast reconstruction. Reconstructions can be adversely affected by PMRT, and fear of reconstruction complications has discouraged adoption of short-course radiation therapy used after lumpectomy. To fill the evidence gap, we conducted a noninferiority trial of hypofractionated versus conventional PMRT in patients undergoing breast reconstruction. The primary outcome was reconstruction complication rate, a composite of wound healing, readmission, capsular contracture, unplanned reoperation, and reconstruction failure. METHODS: Women with unilateral invasive breast cancer with planned immediate or delayed reconstruction and PMRT were randomly assigned (1:1) to 50 Gy (25 fractions/5 weeks) or 42.56 Gy (16 fractions/3 weeks). This study was designed with a noninferiority margin of 10%, assuming a 2-year reconstruction complication rate of 25% with conventional PMRT. Randomization was stratified by immediate versus delayed and autologous versus implant-only reconstruction. RESULTS: Between 2018 and 2021, 898 patients enrolled with a median follow-up of 3.9 years; 825 patients were evaluable for the primary end point. The 24-month reconstruction complication rates were 12.3% (52/422) with hypofractionated PMRT and 10.2% (41/403) with conventional PMRT, corresponding to an estimated difference of -2.1% (95% CI, -6.5 to 2.2). The complication rate was higher (regardless of arm) with implant-only versus autologous reconstruction (odds ratio = 1.65). There was no statistically significant difference in 36-month locoregional recurrence rates: 1.5% (95% CI, 0.7 to 3.2) with hypofractionated and 2.2% (95% CI, 1.1 to 4.3) with conventional PMRT. Acute and late toxicity rates were not statistically different. CONCLUSION: A 16-fraction course of hypofractionated PMRT is safe and noninferior to conventional PMRT in women undergoing breast reconstruction after mastectomy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Poppe MM, Le-Rademacher JJ, Haffty BG, et al. Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505). J Clin Oncol. 2026. PMID: 42863096. doi:10.1200/JCO-26-00474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。